**Name of Journal: *World Journal of Gastrointestinal Oncology***

**Manuscript NO: 34864**

**Manuscript Type: META-ANALYSIS**

**Laparoscopic *vs* open complete mesocolic excision with central vascular ligation for colon cancer: A systematic review and meta-analysis**

Negoi I *et al.* Laparoscopic *vs* open complete mesocolic excision

**Ionut Negoi, Sorin Hostiuc, Ruxandra Irina Negoi, Mircea Beuran**

**Ionut Negoi,** Department of General Surgery, Emergency Hospital of Bucharest, Carol Davila University of Medicine and Pharmacy Bucharest, 014461 Bucharest, Romania

**Sorin Hostiuc**, National Institute of Legal Medicine Mina Minovici, Carol Davila University of Medicine and Pharmacy Bucharest, 014461 Bucharest, Romania

**Ruxandra Irina Negoi**, Department of Anatomy, Carol Davila University of Medicine and Pharmacy Bucharest, 014461 Bucharest, Romania

**Mircea Beuran**, Emergency Hospital of Bucharest, Carol Davila University of Medicine and Pharmacy Bucharest, 014461 Bucharest, Romania

**Author contributions:** Negoi I acquisition of data, analysis and interpretation of data, drafting the article, final approval; Hostiuc S interpretation of data, revising the article, final approval; Negoi RI acquisition of data, revising the article, final approval; Beuran M conception and design of the study, critical revision, final approval; all authors had equally contributed to this scientific paper.

**Conflict-of-interest statement:** The authors have no conflicts to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Ionut** **Negoi, MD, PhD, Senior Lecturer,** Department ofGeneral Surgery, Emergency Hospital of Bucharest, Carol Davila University of Medicine and Pharmacy Bucharest, No 8 Floreasca Street, Sector 1, 014461 Bucharest, Romania. [negoiionut@gmail.com](mailto:negoiionut@gmail.com)

**Telephone:** +40-21-5992308

**Fax:** +40-21-5992257

**Received:** May 29, 2017

**Peer-review started:** June 5, 2017

**First decision:** July 3, 2017

**Revised:** July 8, 2017

**Accepted: September 4, 2017**

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To compare the effectiveness of laparoscopic complete mesocolic excision (CME) with central vascular ligation (L-CME) with its open (O-CME) counterpart.

***METHOD***

We conducted an electronic search of the PubMed/MEDLINE, Excerpta Medica Database, Web of Science Core Collection, Cochrane Center Register of Controlled Trails, Cochrane Database of Systematic Reviews, SciELO, and Korean Journal databases from their inception until May 2017. We considered randomized controlled trials (RCTs) and controlled clinical trials (CCTs) that included patients with colonic cancer comparing L-CME and O-CME.Primary outcomes included the quality of the resected specimen (lymph nodes retrieved, complete mesocolic plane excision, tumor to arterial high tie, resected mesocolon surface). Secondary outcomes included the three-year and five-year overall and disease-free survival rates, recurrence of the disease, surgical data, and postoperative morbidity and mortality.Two authorsof the reviewscreened the methodological quality of the eligible trials and independently extracted data from individual studies.

***RESULTS***

A total of one RCT and eleven CCTs (four from Europe and seven from Asia) met the inclusion criteria for the current meta-analysis. These studies involved 1619 patients in L-CME and 1477 patients in O-CME. The L-CME was associated with the same quality of the resected specimen, with no differences regarding the retrieved lymphnodes (MD = -1.06, 95%CI: -3.65 to 1.53, *P* = 0.42), and tumor to high tie distance (MD = 14.26 cm, 95%CI: -4.30 to 32.82, *P* = 0.13); the surface of the resected mesocolon was higher in the L-CME group (MD = 11.75 cm2, 95%CI: 9.50 to 13.99, *P* < 0.001). The L-CME was associated with a lower rate of blood transfusions (OR = 0.45, 95%CI: 0.27 to 0.75, *P* = 0.002), faster recovery of gastrointestinal function, and less postoperative overall complication rate. The L-CME approach was associated with a statistical significant better three-year overall (OR = 2.02, 95%CI: 1.31 to 3.12, *P* = 0.001, *I2*= 28%) and disease-free (OR = 1.45, 95% CI: 1.00 to 2.10, *P* = 0.05, *I2*= 0%) survival.

***CONCLUSION***

The laparoscopic approach offers the same quality of the resected specimen as the open approach in complete mesocolic excision with central vascular ligation for colon cancer. The laparoscopic complete mesocolic excision with central vascular ligation is superior in all perioperative results and at least non-inferior in long-term oncological outcomes.

**Key words**: Colon cancer; Complete mesocolic excision; D3 lymphadenectomy; Central vascular ligation

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The laparoscopic complete mesocolic excision with central vascular ligation was associated with the same quality of the resected specimen, with no differences regarding the retrieved lymphnodes, and tumor to high tie distance; the surface of the resected mesocolon was higher in the laparoscopic group. Laparoscopy was associated with a lower rate of blood transfusions, faster recovery of gastrointestinal function, and less postoperative overall complication rate. The laparoscopic approach was associated with a statistical significant better three-year overall and disease-free survival.

Negoi I, Hostiuc S, Negoi RI, Beuran B. Laparoscopic *vs* open complete mesocolic excision with central vascular ligation for colon cancer: A systematic review and meta-analysis. *World J Gastrointest Oncol 2017;* In press

**INTRODUCTION**

Complete mesocolic excision (CME) with central vascular ligation (CVL) represents an extension to the colonic cancer of the already standardized resection for rectal cancer. It adheres to the same guiding principle that sharp surgical dissection, following embryological planes, with central vascular ligation, should improve oncological outcomes[[1](#_ENREF_1)].

Hohenberger *et al*[[2](#_ENREF_2)] (2007) published the technical details of a new concept termed CME and central ligation for colonic cancer. During CME with CVL for right-sided tumors, the ileocolic and right colic vessels should be ligated at their origin from the superior mesenteric artery. Transverse colon tumors require transection of the middle colic artery at its origin. Left-sided tumors require transection of the inferior mesenteric artery (IMA) at its origin from the aorta[[3](#_ENREF_3)]. Using CME and CVL, Hohenberger *et al*[[4](#_ENREF_4)] reported a reduction of the local five-year recurrence rate from 6.5% to 3.6% and an increase in the cancer-related five-year survival rate from 82.1% to 89.1%. This specimen-oriented technique is associated with the removal of more tissue compared with standard surgery, a wider distance from the tumor to the high vascular tie (131 *vs* 90 mm, *P* < 0.0001), a longer length of large bowel (314 *vs* 206 mm, *P* < 0.0001), a wider area of removed mesentery (19657 *vs* 11829 mm2, *P* < 0.0001) and a greater lymph node yield (30 *vs* 18, *P* < 0.0001)[[5](#_ENREF_5)]. These differences may partially explain the higher reported survival rates with CME and CVL.

One should note the similarities between D3 lymphadenectomies, recommended as a standard of care for stage II and III colon cancer in Eastern countries, and Western CME[[3](#_ENREF_3),[6](#_ENREF_6)]. The Japanese nomenclature includes D1 as pericolic (close to the bowel wall), D2 as intermediate (along the feeding artery), and D3 as main (at the origin of the feeding artery) lymph nodes. For right-sided tumors, a D3 lymphadenectomy requires the transection of the feeding arteries next to their origin from the superior mesenteric artery. In left-sided cancers, a D3 lymphadenectomy requires transection of the IMA close to its aortic origin[[7](#_ENREF_7)].

Current evidence is consistent with a faster postoperative recovery for laparoscopic colectomies compared with the open approach; the former is not associated with any negative impact regarding local recurrence and survival rates. Therefore, according to the latest National Comprehensive Cancer Network guidelines, the laparoscopic approach is preferred given access to a surgeon with experience in advanced minimally invasive procedures[[8](#_ENREF_8)].

The objective of this systematic review and meta-analysis is to summarize the current evidence regarding laparoscopic CME (L-CME) and to compare its effectiveness with its open (O-CME) counterpart.

**MATERIALS AND METHODS**

This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement[[9](#_ENREF_9)]. Electronic search, study selection, data extraction, and quality assessment was performed independently by two reviewers.

***Data sources and search strategy***

We conducted an electronic search to identify all published randomized controlled trials (RCTs) and controlled clinical trials (CCTs) using the following databases: United States National Library of Medicine – National Institutes of Health PubMed/MEDLINE, EMBASE, Web of Science Core Collection, Cochrane Center Register of Controlled Trails (CENTRAL), Cochrane Database of Systematic Reviews, SciELO, and Korean Journal databases from their inception until May 2017. We did not use any language restrictions. The most recent search in PubMed was performed in May 2017.

We constructed the search strategy using various combinations of terms related to CME or D3 lymphadenectomy using an open or laparoscopic approach to colon cancer. We used in different combinations the following key words: colon, cancer, complete mesocolic excision, central vascular ligation, D3 lymphadenectomy, minimally invasive, laparoscopy, open, surgery, colectomy and resection. These words were identified as truncated words in the title, abstract, or in the medical subject headings (MeSH). We additionally used electronic and manual cross-referencing to find other relevant sources. The search strategy used in PubMed/Medline was: [colon (MeSH Terms)] OR colonic (Title/Abstract) OR lower intestinal (Title/Abstract) OR large bowel (Title/Abstract) AND cancer (MeSH Terms) OR neoplasia (Title/Abstract) OR neoplasm (Title/Abstract) OR tumor (Title/Abstract) AND laparoscopy(MeSH Terms) OR minimally invasive(Title/Abstract) OR laparoscopic (Title/Abstract) AND complete mesocolic excision (Title/Abstract) OR central vascular ligation (Title/Abstract) OR D3 lymphadenectomy (Title/Abstract).

***Trial selection***

**Study eligibility criteria**: We considered RCTs and CCTs comparing open with laparoscopic CME or D3 lymphadenectomy as eligible for inclusion if they included patients with colonic cancer.

***Outcome measures***

**Primary outcome**: Quality of the resected specimen (lymph nodes retrieved, complete mesocolic plane excision, tumor to arterial high tie, resected mesocolon surface).

**Secondary outcomes:** Three-year and five-year overall and disease-free survival rates, recurrence of the disease, surgical data (operation time, length of the abdominal incision, conversion rate), intraoperative complications, blood loss, postoperative complications (anastomotic leakage, wound infections, overall complications), length of hospital stay, thirty-day mortality, immunologic response, quality of life, and cost.

***Data extraction***

Two authors[[10](#_ENREF_10)](Negoi and Hostiuc)assessed the methodological quality of the eligible trials and independently extracted data from individual studies using a data-extraction form. We extracted the following data: year of publication, source, title, first author, contact address, criteria for patient inclusion and exclusion, sample size, baseline characteristics, and patient characteristics including mean age, sex ratio, location of the tumor, number of patients assigned to each treatment group, and details of the intervention regimens. We registered the following outcomes: one-, three- and five-year overall and disease-free survival rates, number of removed lymph nodes, length of the resected colon, resection of the mesocolic plane, operation time, length of hospital stay, number and frequency of postoperative complications, and quality of life.

***Assessment of risk of bias***

To assess the risk of bias, we used the Cochrane Collaboration tool for RCTs. This tool grades the random sequence generation, allocation concealment, blinding of participant and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases[[11](#_ENREF_11)]. To evaluate the non-randomized trials, we used the methodological index of non-randomized studies (MINORS)[[12](#_ENREF_12)]. We scored all of the 12 methodological items for non-randomized comparative studies as follows: 0 – not reported, 1 – reported but inadequate, or 2 – reported and adequate. The global ideal score for comparative (non-comparative) studies was 24.

***Statistical analysis***

For statistical analysis, we used Review Manager Software 5.3.5 (The Nordic Cochrane Centre, Copenhagen, Denmark)[[11](#_ENREF_11)] provided by the Cochrane Collaboration and OpenMetaAnalyst[[13](#_ENREF_13)] with metaphor package[[14](#_ENREF_14)] as statitstical softwares. We selected the mean difference (MD) as an effect measure for continuous data and the odds ratio (OR) for dichotomous data; we also reported the 95% confidence interval (95%CI). In cases of continuous data presented as median and range, we estimated the mean and standard deviation according to the methods described by Hozo *et al*[[15](#_ENREF_15)]. We used Chi-square and *I2* statistics to assess the studies’ heterogeneity and explain the total variation observed between the studies that be generated by the differences between the trials rather than the sampling error (chance). An *I2*value ≤ 25% indicates less heterogeneity, an *I2*value > 25% but ≤ 75% indicates a moderate heterogeneity, and *I2*values > 75% indicate higher heterogeneity[[16](#_ENREF_16)]. We explored the reasons behind the statistical heterogeneity using sensitivity analyses and the exclusion of specific studies. We used fixed-effect model analysis for outcomes with low heterogeneity. If we found clinical heterogeneity between included studies due to differences with respect to eligibility criteria (study population), the type of surgical technique, and lacking or differing definitions of outcomes, we performed meta-analysis by applying a random-effect model (the DerSimonian–Laird method)[[17](#_ENREF_17)]. We used Begg's funnel plot and Egger's test for assessing publication bias[[18](#_ENREF_18)]. The statistical significance was defined as *P* < 0.1 in Egger’s test and *P* < 0.05 for the other statistical tests. To correct possible publication bias, we performed trim and fill analysis[[19](#_ENREF_19)]. The statistical methods of this study were reviewed by Sorin Hostiuc from the Department of Legal Medicine and Bioethics, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

**RESULTS**

***Description of studies***

**Results of the search:** The initial electronic and manual literature searches revealed 174 full-text articles. A total of one RCT (from Japan)[[20](#_ENREF_20),[21](#_ENREF_21)] and eleven CCTs (four from Europe and seven from Asia)[[22-32](#_ENREF_22)] met the inclusion criteria for the qualitative and quantitative (meta-analysis) synthesis; these studies involved 1619 patients in L-CME and 1477 patients in O-CME. Eleven studies were published in English and one in Chinese. The reasons for exclusion in each stage of the process are shown in Figure 1.

**Included studies:** The characteristics of the included studies are summarized in Table 1. All of the studies were published between 2012 and 2016, the RCT being published in 2014. The sample size of the studies ranged from 23 to 533 patients. The CME or D3 lymphadenectomy was defined as dissection along the Told’s fascia space and a high (apical or central) ligation of the feeding vessel. Colonic mobilization was conducted using a medial-to-lateral or a lateral-to-medial approach according to the surgeon’s preference. For right-sided tumors, the vascular pedicles were divided at their origin together with removal of the draining lymph nodes along the border of the superior mesenteric vein. For left-sided tumors, removal of the central lymph nodes from the origin of the inferior mesenteric artery was performed with high ligation or with preservation of the left colic artery. In the JCOG 0404 study, the accredited surgeons had completed more than 30 laparoscopic and 30 open colorectal resections[[20](#_ENREF_20)]. In all of the other studies, the procedures were performed or supervised by colorectal surgeons. Conversion to laparotomy was defined as the extension of the abdominal incision more than eight cm or as the inability to complete the dissection fully laparoscopically. The reported rate of conversion to laparotomy was between 2.82% and 7.6%[[20](#_ENREF_20),[22-32](#_ENREF_22)]. Transverse colon cancers were excluded from the JCOG 0404 study[[20](#_ENREF_20)]. Storli *et al*[[30](#_ENREF_30)] performed 9 (7.3%) transverse colectomies in the open approach but none in the laparoscopic group. In a second paper, Storli *et al*[[22](#_ENREF_22)] published their experience regarding CME only in transverse colon cancer. Gouvas *et al*[[31](#_ENREF_31)] managed all of the transverse colon cancers using an extended right hemicolectomy. Munkedal *et al*[[25](#_ENREF_25)] excluded all cancers in the transverse colon or flexures from their analysis. Bae *et al*, Han *et al*, and Zhao *et al*[[26-28](#_ENREF_26)] managed all cases by a right or extended right hemicolectomy. All studies exhibited remarkable similar exclusion criteria: stage IV disease and emergency surgery. All of the studies described the technique of laparoscopic CME. Perioperative care was not described in most trials.

The patient demographics and baseline clinical data were similar between the treatment groups; the L-CME group exhibited a mean age of 69.91 years, and the O-CME group exhibited a mean age of 65.41 years. Women comprised 46.20% and 41.23% of the L-CME and O-CME patients, respectively. None of the studies were blinded, and all of the studies were powered to demonstrate the non-inferiority of the laparoscopic approach.

**Excluded studies:** We excluded all studies in which the surgical technique did not comply with CME or D3 lymphadenectomy principles[[33-42](#_ENREF_33)]. We also excluded studies based on the hand-assisted laparoscopic technique[[43](#_ENREF_43),[44](#_ENREF_44)]. Due to the probability of overlapping patients, we have excluded first report of Kim *et al*[[45](#_ENREF_45)] which includes only T4 patients.

***Risk of bias in the included studies***

The risk of bias in the one Japanese RCT was low in all domains[[20](#_ENREF_20)]. Although blinding of patients and medical personnel was not performed in either trial, the endpoints were considered to be objective, particularly when they were supported by photos. The prospective and retrospective non-randomized studies had good MINORS scores, although the risk of selection, performance, and detection bias was high (Table 2). As expected, the prospective observational studies[[22](#_ENREF_22)-[23](#_ENREF_23),[25](#_ENREF_25),[30](#_ENREF_30)-[31](#_ENREF_31)] had a higher methodological quality comparing with the retrospective studies[[24](#_ENREF_24),[26-29](#_ENREF_26)].

***Effects of intervention***

**Overall survival:** Three-year overall survival was reported by four studies, including 1010 patients (Table 3). The laparoscopic approach was associated with a statistical significant better three-year overall survival, with an OR of 2.02 (95%CI: 1.31 to 3.12, *P* = 0.001, *I2* = 28%). The five-year overall survival was reported by three studies, with a high heterogeneity between them (*I2* = 63%). The combined data revealed no statistical significant differences between the L-CME and O-CME (OR = 0.77, *P* = 0.38, 95%CI: 0.44 to 1.37) (Figure 2). Meta-regression of studies on three-year overall survival according to the number of included patients revealed a trend, although not statistical significant (omnibus *P* = 0.127), for decreasing of the size of the effect with increasing the number of patients (Figure 3A). The subgroup analysis of studies that include or not only right sided colon cancers, reveled statistical significant results irrespective of that (*P* = 0.003 and *P* = 0.018, respectively) (Figure 3B). On the other hand, the cumulative meta-analysis showed a progressively increasing of the size effect while experience is accumulating (Figure 3C).

***Disease-free survival***

Three studies, with a total of 686 patients, reported the three-year DFS with a low heterogeneity between them (*I2* = 0%). However, to adjust for possible methodological differences we used the random-effects model, which revealed that the laparoscopic approach is associated with a statistical significant better three-year DFS (OR = 1.45, 95%CI: 1.00 to 2.10, *P* = 0.05) (Figure 4). Meta-regression of studies on three-year overall survival according to the number of the included patients revealed a trend, although not statistical significant (Omnibus *P* = 0.718), for decreasing of the size of the effect with increasing the number of patients (Figure 5).

***Local and distant recurrences***

The local recurrence rate was presented by five studies, including 1233 patients. In the fixed-effect meta-analysis there were no statistical significant differences between L-CME and O-CME (OR = 0.67, 95%CI: 0.38 to 1.17, *P* = 0.16, *I2* = 0%) (Figure 6).

The distant recurrence rate was presented by four studies, with a moderate heterogeneity between them (*I2* = 40%). In the random-effects meta-analysis there were no statistical significant differences between the two groups (OR = 0.98, 95%CI: 0.61 to 1.58, *P* = 0.94). Using Egger's test, no publication bias was found for local (*t* = 0.22, *P* = 0.42) or distant recurrences (*t* = 0.38, *P* = 0.36).

The port size metastasis rate was reported by two studies including 494 patients, with a low heterogeneity between them (*I2* = 0%). In the fixed-effect analysis model there was no difference regarding the port size metastasis rate between laparoscopic and open CME (OR = 1.52, 95%CI: 0.20 to 11.42, *P* = 0.69).

***Quality of the resected specimen***

Standardized evaluation of the resected specimen and grading its quality are objective measures that predict recurrence rate and survival. These data are correlated with the accuracy of the surgical technique.

***Lymphnodes retrieved***

Ten studies reported the number of retrieved lymph nodes for 1376 L-CME patients and 1271 O-CME patients. There was a high heterogeneity between the studies (*I2* = 92%). In the random-effects model, we found no statistically significant mean difference between L-CME and O-CME (MD = -1.06, 95%CI: -3.65 to 1.53, *P* = 0.42) (Figure 7). In order to address the observed heterogeneity, we performed subgroup analysis according to the number of included patients (less or more than 100 patients in each group) and the geographical location of the study (Europe and Asia). The subgroup analysis revealed a high heterogeneity between studies with less than (*I2* = 85%) or more (*I2* = 83%) than 100 patients into laparoscopy or open group. The results remained with no statistical significance into the two subgroups. Studies coming from Europe showed a high heterogeneity (*I2* = 90%) and with no differences regarding the number of retrieved lymphnodes (*P* = 0.19). Studies published in Asia had also a high heterogeneity (*I2* = 77%), and no statistical significant difference between L-CME and O-CME (*P* = 0.56). Meta-regression of retrieved lymphnodes according to the number of patients revealed that the equivalence between laparoscopic and open approach is stronger with the increased experience in laparoscopic approach (number of the included patients - omnibus *P* = 0.314, Figure 8A; and year of publishing of the study, Figure 8B).

***Tumor to high tie distance***

The mean distance from the tumor to the arterial high tie was reported by two studies that included 132 patients in the L-CME group and 120 patients in the O-CME group; we noted high heterogeneity among the studies (*I2* = 92%). Using the random-effects model, we did not find any statistically significant difference between the L-CME and O-CME groups (MD = 14.26 cm, 95%CI: -4.30 to 32.82, *P* = 0.13) (Figure 9).

***Surface of the resected mesocolon***

The surface of the resected mesocolon was reported by two studies with 132 patients in the L-CME group and 120 patients in the O-CME group. The surface of the resected mesocolon was larger in the L-CME group (MD = 11.75 cm2, 95%CI: 9.50 to 13.99, *P* < 0.001) (Figure 10).

***Complete mesocolic plane excision rate***

One study reported the rate of complete mesocolic plane excision, with no statistically significant difference between the laparoscopic and open approach (OR = 0.77, 95%CI: 0.20 to 2.96).

***Duration of surgery***

The duration of surgery was reported by seven studies, with a high heterogeneity between data (*I2* = 94%). The L-CME group had a longer duration of surgery with a mean difference of 26.26 min (95%CI: 5.06 to 47.46, *P* = 0.02). Using Egger's test, no publication bias was found (*t* = 0.71, *P* = 0.26).

***Incision length***

The incision length was reported by two studies, including 586 patients in the L-CME group and 573 patients in the O-CME group. Patients from the laparoscopic group had a shorter incision, with a mean difference of 14.01 cm (95%CI: -14.35 to -13.66, *P* < 0.001).

***Blood loss***

Intraoperative blood-loss data were presented by five studies, with 964 and 904 patients in the L-CME and O-CME, respectively. Due to the high heterogeneity of the data (*I2* = 89%) we have used the random-effect analysis. The laparoscopic approach was associated with statistical significant lower intraoperative bleeding, with a mean difference of 52.11 mL (95%CI: -78.57 to -25.65, *P* < 0.001). Using Egger's test, no publication bias was found (*t* = 0.17, *P* = 0.44). Should be noted the clinical significance of lower intraoperative blood loss associated with laparoscopic approach, which was translated in a lower need for transfusion rate (OR = 0.45, 95%CI: 0.27 to 0.75, *P* = 0.002). Two studies, including a total of 1272 patients, reported the need for blood transfusions, with a low heterogeneity between them (*I2* = 0%) (Figure 11).

***Recovery of gastrointestinal function***

The time to first flatus was reported by four studies, including 914 and 857 patients in the L-CME and O-CME, respectively. In the random-effects meta-analysis the laparoscopic approach was associated with a shorter time interval to first flatus, with a mean difference of 0.90 d (95%CI: -1.46 to -0.34, *P* = 0.002, *I2* = 97%).

The time to liquid diet was reported by five studies, with a high heterogeneity between them (*I2* = 98%). The time to liquid diet was shorter for the L-CME patients, with a mean difference of 1.84 d (95%CI: -2.93 to -0.74, *P* = 0.001).

***Short-term morbidity and mortality***

Seven studies presented the postoperative overall morbidity, and these studies included 1116 patients in the L-CME group and 1028 patients in the O-CME group. There was low statistical heterogeneity among the studies (*I2* = 0%). The L-CME procedure was associated with a lower postoperative morbidity (OR = 0.57, 95%CI: 0.46 to 0.71, *P* < 0.001) (Figure 12).

Wound complications, reported by eight studies, were significantly less frequent in the L-CME group (OR = 0.43, 95%CI: 0.30 to 0.61, *P* < 0.001). There was no statistical heterogeneity among the studies (*I2* = 0%).

There was no difference between the two groups regarding postoperative bleeding (OR = 1.20, 95%CI: 0.46 to 3.12, *P* = 0.71), anastomotic leakage (OR = 0.82, 95%CI: 0.0.54 to 1.25, *P* = 0.36), need for reoperation (OR = 0.59, 95%CI: 0.28 to 1.23, *P* = 0.16), and pulmonary complications (OR = 0.61, 95%CI: 0.20 to 1.84, *P* = 0.38).

The 30-d mortality was reported by six studies with 1158 patients in the L-CME group and 1079 patients in the O-CME group. There was low heterogeneity among the studies (*I2* = 0%). In the fixed-effects meta-analysiswe observed no statistically significant difference between the L-CME and O-CME groups (OR = 0.42, 95%CI: 0.16 to 1.12).

Nine studies, with 1340 and 1233 patients in the L-CME and O-CME, respectively reported the hospital stay. There was a high heterogeneity between the studies (*I2* = 91%). In the random-effects meta-analysis we found a statistical significant lower hospital stay for laparoscopic group, with a mean difference of 4.07 d (95%CI: -5.87 to -2.28, *P* < 0.001).

***Risk of bias across studies***

We conducted sensitivity analysis to assess statistical heterogeneity based on excluding specific studies with a high risk of bias (Figure 13). There were no relevant changes in the overall effects of the quantitative synthesis. Our analysis of the funnel plots reveals no significant asymmetries for the studied outcomes (Figures 14 and 15).

**DISCUSSION**

Our meta-analysis revealed that laparoscopic CME with CVL for colon cancer offers the same quality of the resected specimen as the open approach, being superior in all perioperative results and at least non-inferior in long-term oncological outcomes. Although not addressed the complete mesocolic excision or D3 lymphadenectomy technique, the equivalence of laparoscopy in terms of resected lymphnodes was showed in four large, multicenter, studies—Clinical Outcomes of Surgical Therapy (COST), Conventional *vs* Laparoscopic-Assisted Surgery in Colorectal Cancer (CLASSIC), Colon Cancer Laparoscopic or Open Resection I (COLOR I), and the Australasian Randomized Clinic Study Comparing Laparoscopic and Conventional Open Surgical Treatments for Colon Cancer (ALCCaS); the mean number of resected lymph nodes was 10.13 in the laparoscopic group and 10.14 in the open group[[40-42](#_ENREF_40)]. An RCT from Taiwan comparing open with laparoscopic left-sided D2 resections for stage II or III colon cancer reported 16 ± 3 dissected lymph nodes in its laparoscopic group and 16 ± 6 in its open group[[33](#_ENREF_33)]. The long-term oncological outcomes between the L-CME and O-CME groups were also comparable; there were no differences regarding the local and distant recurrence rate, the three- and five-year overall rates and the disease-free survival rates. In our study, the three-year overall and disease-free survival were superior in the laparoscopic group; however, should be noted the extensive experience in laparoscopy of the reporting centers. In Barcelona study, the laparoscopic approach was associated with a slight increase in survival rate, a faster postoperative recovery, and a shorter in-hospital stay duration[[38](#_ENREF_38)]. In the COLOR study, 1248 patients were randomized for open or laparoscopic colon resection[[46](#_ENREF_47)]. After a median follow-up of 53 mo, the combined three-year, disease-free survival rate was 74.2% in the laparoscopic group and 76.2% in the open group (*P* = 0.70). The combined three-year overall survival rate was 81.8% in the laparoscopic group and 84.2% in the open group (*P* = 0.45). The authors concluded that a difference in the three-year, disease-free survival rate could not be ruled out due to limitations of the study[[46](#_ENREF_47)]. In the CLASSIC trial, 794 patients with colorectal cancer were randomized for open or laparoscopic resection[[47](#_ENREF_47)]. An analysis of the subgroup of patients with colon cancer, 140 in the open group and 273 in the laparoscopic group, did not reveal any differences in terms of three-year overall survival rates (*P* = 0.51). After a median follow-up of 62.9 mo, there were no statistically significant differences in overall survival and disease-free survival rates[[48](#_ENREF_49)]. In the COST study, 872 patients were randomized to receive an open or laparoscopic colectomy[[49](#_ENREF_47)]. The 3- and 5-year follow-ups revealed no differences regarding recurrence rate and overall survival rates[[49,50](#_ENREF_47)].

We found a longer duration of surgery in the laparoscopic group. However, all the perioperative outcomes, such as blood loss, need for transfusion, incision length, wound complications, and thirty-day overall morbidity were less frequent in the laparoscopic group. In the COST, CLASSIC, COLOR I, and ALCCaS trials, the mean duration of surgery was 145–180 compared to 95–135 min, the hospital stay was 5–10 *vs* 6–11 d, the 30-d morbidity was 21%–38% *vs* 20%–45%, and the 30-d mortality was 0.5%–4.0% *vs* 0.7%–5.0% in the laparoscopic and open groups, respectively[[40-42](#_ENREF_40),[49](#_ENREF_50)]. Liang *et al*[[33](#_ENREF_33)]found a longer operative time for left-sided resections (224.4 ± 44.8 *vs* 184.0 ± 30.6 min), less blood loss (54 ± 12 *vs* 240 ± 34 mL), a shorter wound incision (10.6 ± 1.6 *vs* 18 ± 3.1 cm) for the laparoscopic approach, but there were no statistically significant differences regarding total postoperative complications (20 *vs* 29, *P* = 0.15).

Our meta-analysis showed that patients from the laparoscopic group had a shorter hospital stay and a shorter recovery time to regain gastrointestinal function. This result is consistent with the current evidence that supported earlier recovery of bowel functioning and oral diet with an in-hospital stay duration 1.7 d shorter in the laparoscopic group[[51](#_ENREF_52)]. The studies included in the current meta-analysis did not evaluate how surgery affected immune functioning. According to Liang *et al*[[33](#_ENREF_33)], the postoperative proinflammatory response, evaluated by C-reactive protein and the erythrocyte sedimentation rate and postoperative immunosuppression and assessed by alteration of lymphocyte counts and the CD4+/CD8+ ratio, was significantly less in the laparoscopic group (*P* < 0.001).

An important concern regarding laparoscopic colon surgery is the reproducibility of results given the nature of multicenter, specialized centers and the heterogeneity of general surgeons. All surgical procedures from the studies included in this meta-analysis were performed by highly experienced or accredited surgeons. An analysis of the short-term outcomes of colon and rectal laparoscopic resections in Sydney South West Area Health Service revealed a lower morbidity (28.8 *vs* 54.4%, *P* < 0.001), fewer transfusions (0.4 *vs* 0.7 units, *P* = 0.0028), a longer operative time (24.1 min, *P* < 0.0001) and a shorter length of stay (7 *vs* 10 d, *P* = 0.0011) for laparoscopic procedures[[52](#_ENREF_53)]. Dobbins *et al*[53]published the results of laparoscopic resections for colon and rectal cancer from all of the public and private hospitals in New South Wales, Australia. The laparoscopic colon resections were associated with a reduced rate of extended stay (OR = 0.60, 95%CI: 0.49–0.72) and 28-d readmissions (OR = 0.86, 95%CI: 0.74–0.99). Survival benefits for laparoscopy, regarding cancer-specific survival, were observed in higher-caseload hospitals but not in lower-caseload hospitals[[53](#_ENREF_54)].

The current meta-analysis has as a main limitation the clinical heterogeneity of the included studies, and caution should be exercised when interpreting its results. This meta-analysis involves several types of study designs, including retrospective, prospective, and RCT. There is an increased heterogeneity of the tumor localization on the colon, with the transverse colon cancers being excluded from the analysis in two studies, while the others included them into the right/extended right hemicolectomy group. Excepting the one randomized controlled trial, the experience in minimally invasive surgery of the surgeons from the laparoscopic group is not quantified, although all procedures were performed or supervised by trained colorectal surgeons. However, using random-effects meta-analysis, with subgroup analysis and meta-regression, we limited the variance of the included outcomes.

In summary, the current data suggest that the laparoscopic approach offers the same quality of resected specimens as the open approach in CME with CVL for colon cancer while maintaining all of the short-term benefits of a minimally invasive approach. Although a specimen-oriented surgical dissection in colon cancer *via* a laparoscopic approach is challenging, the magnification and predisposition to details of a minimally invasive technique are associated with a lower postoperative morbidity.

**COMMENTS**

***Background***

Complete mesocolic excision with central vascular ligation represents an extension to the colonic cancer of the already standardized resection for rectal cancer. It adheres to the same guiding principle that sharp surgical dissection, following embryological planes, with central vascular ligation, should improve oncological outcomes. The technical details of this new concept were published in 2007.

***Research frontiers***

A high-level evidence that laparoscopic approach offers the same quality of the resected specimen as open surgery for complete mesocolic excision with central vascular ligation for colon cancer is lacking.

***Innovations and breakthroughs***

Current evidence is consistent with a faster postoperative recovery for laparoscopic colectomies compared with the open approach; the former is not associated with any negative impact regarding local recurrence and survival rates. This study reveals that laparoscopy offers the same quality of the resected specimen as the open approach in complete mesocolic excision with central vascular ligation for colon cancer. The laparoscopic complete mesocolic excision with central vascular ligation is superior in all perioperative results and at least non-inferior in long-term oncological outcomes.

***Applications***

Due to all advantages of laparoscopy, the teaching and mentoring of minimally invasive techniques for colon resections should be accentuated, in order to increase the proportion of laparoscopic over open procedures.

***Terminology***

During complete mesocolic excision with central vascular ligation for right-sided tumors, the ileocolic and right colic vessels should be ligated at their origin from the superior mesenteric artery, medial (patient left-hand side) to the superior mesenteric vein. Transverse colon tumors require transection of the middle colic artery at its origin. Left-sided tumors require transection of the inferior mesenteric artery at its origin from the aorta.

***Peer-review***

This is an interesting meta-analysis and review of a highly debatable topic in surgery, the consensus about laparoscopic *vs* open surgery in high ligation.

**REFERENCES**

1 **Negoi I**, Hostiuc S, Runcanu A, Negoi RI, Beuran M. Superior mesenteric artery first approach versus standard pancreaticoduodenectomy: a systematic review and meta-analysis. *Hepatobiliary Pancreat Dis Int* 2017; **16**: 127-138 [PMID: 28381375 DOI: 10.1016/S1499-3872(16)60134-0]

2 **Hohenberger W**, Merkel S, Weber K. [Lymphadenectomy with tumors of the lower gastrointestinal tract]. *Chirurg* 2007; **78**: 217-225 [PMID: 17333036 DOI: 10.1007/s00104-007-1311-y]

3 **West NP**, Kobayashi H, Takahashi K, Perrakis A, Weber K, Hohenberger W, Sugihara K, Quirke P. Understanding optimal colonic cancer surgery: comparison of Japanese D3 resection and European complete mesocolic excision with central vascular ligation. *J Clin Oncol* 2012; **30**: 1763-1769 [PMID: 22473170 DOI: 10.1200/JCO.2011.38.3992]

4 **Hohenberger W**, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. *Colorectal Dis* 2009; **11**: 354-364; discussion 364-365 [PMID: 19016817 DOI: 10.1111/j.1463-1318.2008.01735.x]

5 **West NP**, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. *J Clin Oncol* 2010; **28**: 272-278 [PMID: 19949013 DOI: 10.1200/JCO.2009.24.1448]

6 **Watanabe T**, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. *Int J Clin Oncol* 2012; **17**: 1-29 [PMID: 22002491 DOI: 10.1007/s10147-011-0315-2]

7 **Feng H**, Zhao XW, Zhang Z, Han DP, Mao ZH, Lu AG, Thasler WE. Laparoscopic Complete Mesocolic Excision for Stage II/III Left-Sided Colon Cancers: A Prospective Study and Comparison with D3 Lymph Node Dissection. *J Laparoendosc Adv Surg Tech A* 2016; **26**: 606-613 [PMID: 27183112 DOI: 10.1089/lap.2016.0120].]

8 **NCCN. Colon Cancer,** Version 2.2017. NCCN Clin Pract Guidel Oncol, 2017

9 **Liberati A**, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; **339**: b2700 [PMID: 19622552 DOI: 10.1136/bmj.b2700]

10 **Negoi I**, Hostiuc S, Paun S, Negoi RI, Beuran M. Extralevator vs conventional abdominoperineal resection for rectal cancer-A systematic review and meta-analysis. *Am J Surg* 2016; **212**: 511-526 [PMID: 27317475 DOI: 10.1016/j.amjsurg.2016.02.022]

11 **The Cochrane C.** Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], 2011

12 **Slim K**, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. *ANZ J Surg* 2003; **73**: 712-716 [PMID: 12956787 DOI: 10.1046/j.1445-2197.2003.02748.x]

13 **Byron W,** Dahabreh I, Trikalinos A, Lau J, Trow P, Schmid C, 49 (2012): 5. Closing the Gap between Methodologists and End-Users: R as a Computational Back-End. *J Statistical Software* 2012; **49**: 1-15 [DOI: 10.18637/jss.v049.i05]

14 Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *J Statistical Software* 2010; 36: 1-48 [DOI: 10.18637/jss.v036.i03]

15 **Hozo SP**, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* 2005; **5**: 13 [PMID: 15840177 DOI: 10.1186/1471-2288-5-13]

16 **Chootrakool H**, Shi JQ, Yue R. Meta-analysis and sensitivity analysis for multi-arm trials with selection bias. *Stat Med* 2011; **30**: 1183-1198 [PMID: 21538449 DOI: 10.1002/sim.4143]

17 **DerSimonian R**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188 [PMID: 3802833 DOI: 10.1016/0197-2456(86)90046-2]

18 **Egger M**, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315**: 629-634 [PMID: 9310563 DOI: 10.1136/bmj.316.7129.469]

19 **Duval S**, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000; **56**: 455-463 [PMID: 10877304 DOI: 10.1111/j.0006-341X.2000.00455.x]

20 **Yamamoto S**, Inomata M, Katayama H, Mizusawa J, Etoh T, Konishi F, Sugihara K, Watanabe M, Moriya Y, Kitano S; Japan Clinical Oncology Group Colorectal Cancer Study Group. Short-term surgical outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage II/III colon cancer: Japan Clinical Oncology Group Study JCOG 0404. *Ann Surg* 2014; **260**: 23-30 [PMID: 24509190 DOI: 10.1097/SLA.0000000000000499]

21 **Nakajima K**, Inomata M, Akagi T, Etoh T, Sugihara K, Watanabe M, Yamamoto S, Katayama H, Moriya Y, Kitano S. Quality control by photo documentation for evaluation of laparoscopic and open colectomy with D3 resection for stage II/III colorectal cancer: Japan Clinical Oncology Group Study JCOG 0404. *Jpn J Clin Oncol* 2014; **44**: 799-806 [PMID: 25084776 DOI: 10.1093/jjco/hyu083]

22 **Storli KE**, Eide GE. Laparoscopic Complete Mesocolic Excision versus Open Complete Mesocolic Excision for Transverse Colon Cancer: Long-Term Survival Results of a Prospective Single Centre Non-Randomized Study. *Dig Surg* 2016; **33**: 114-120 [PMID: 26734758 DOI: 10.1159/000442716]

23 **Kim IY**, Kim BR, Choi EH, Kim YW. Short-term and oncologic outcomes of laparoscopic and open complete mesocolic excision and central ligation. *Int J Surg*2016; **27**: 151-157 [PMID: 26850326 DOI: 10.1016/j.ijsu.2016.02.001]

24 **Huang JL**, Wei HB, Fang JF, Zheng ZH, Chen TF, Wei B, Huang Y, Liu JP. Comparison of laparoscopic versus open complete mesocolic excision for right colon cancer. *Int J Surg* 2015; **23**: 12-17 [PMID: 26318966 DOI: 10.1016/j.ijsu.2015.08.037]

25 **Munkedal DL**, West NP, Iversen LH, Hagemann-Madsen R, Quirke P, Laurberg S. Implementation of complete mesocolic excision at a university hospital in Denmark: An audit of consecutive, prospectively collected colon cancer specimens. *Eur J Surg Oncol* 2014; **40**: 1494-1501 [PMID: 24947074 DOI: 10.1016/j.ejso.2014.04.004]

26 **Han DP**, Lu AG, Feng H, Wang PX, Cao QF, Zong YP, Feng B, Zheng MH. Long-term outcome of laparoscopic-assisted right-hemicolectomy with D3 lymphadenectomy versus open surgery for colon carcinoma. *Surg Today* 2014; **44**: 868-874 [PMID: 23989942 DOI: 10.1007/s00595-013-0697-z]

27 **Bae SU**, Saklani AP, Lim DR, Kim DW, Hur H, Min BS, Baik SH, Lee KY, Kim NK. Laparoscopic-assisted versus open complete mesocolic excision and central vascular ligation for right-sided colon cancer. *Ann Surg Oncol* 2014; **21**: 2288-2294 [PMID: 24604585 DOI: 10.1245/s10434-014-3614-9]

28 **Zhao LY**, Chi P, Ding WX, Huang SR, Zhang SF, Pan K, Hu YF, Liu H, Li GX. Laparoscopic *vs* open extended right hemicolectomy for colon cancer. *World J Gastroenterol* 2014; **20**: 7926-7932 [PMID: 24976728 DOI: 10.3748/wjg.v20.I24.7926]

29 **Cong J,** Chen C, Feng Y, Ma M, Xia Z, Liu D. Comparison of short-term outcomes between laparoscopic and open complete mesocolic excision/D3 radical operation for stage II/III right hemicolon carcinoma. *Chin J Clin Oncol* 2014; **41**: 1591-1596 [DOI: 10.3969/j.issn.1000-8179.20141276]

30 **Storli KE**, Søndenaa K, Furnes B, Eide GE. Outcome after introduction of complete mesocolic excision for colon cancer is similar for open and laparoscopic surgical treatments. *Dig Surg* 2013; **30**: 317-327 [PMID: 24022524 DOI: 10.1159/000354580]

31 **Gouvas N**, Pechlivanides G, Zervakis N, Kafousi M, Xynos E. Complete mesocolic excision in colon cancer surgery: a comparison between open and laparoscopic approach. *Colorectal Dis* 2012; **14**: 1357-1364 [PMID: 22390358 DOI: 10.1111/j.1463-1318.2012.03019.x]

32 **Sun YW**, Chi P, Lin HM, Lu XR, Huang Y, Xu ZB, Huang SH. [Comparison of efficacy between laparoscopic versus open complete mesocolic excision for colon cancer]. *Zhonghua Wei Chang Wai Ke Za Zhi* 2012; **15**: 24-27 [PMID: 22287345 DOI: 10.3760/cma.j.issn.1671-0274.2012.01.009]

33 **Liang JT**, Huang KC, Lai HS, Lee PH, Jeng YM. Oncologic results of laparoscopic versus conventional open surgery for stage II or III left-sided colon cancers: a randomized controlled trial. *Ann Surg Oncol* 2007; **14**: 109-117 [PMID: 17066227 DOI: 10.1245/s10434-006-9135-4]

34 **Kaiser AM**, Kang JC, Chan LS, Vukasin P, Beart RW Jr. Laparoscopic-assisted vs. open colectomy for colon cancer: a prospective randomized trial. *J Laparoendosc Adv Surg Tech A* 2004; **14**: 329-334 [PMID: 15684776 DOI: 10.1089/lap.2004.14.329]

35 **Ramacciato G**, D'Angelo F, Aurello P, Nigri G, Valabrega S, Pezzoli F, Ravaioli M, Cescon M, Cucchetti A, Lauro A, Del Gaudio M, Ercolani G. [Right hemicolectomy for colon cancer: a prospective randomised study comparing laparoscopic vs. open technique]. *Chir Ital* 2008; **60**: 1-7 [PMID: 18389741]

36 **King PM**, Blazeby JM, Ewings P, Franks PJ, Longman RJ, Kendrick AH, Kipling RM, Kennedy RH. Randomized clinical trial comparing laparoscopic and open surgery for colorectal cancer within an enhanced recovery programme. *Br J Surg* 2006; **93**: 300-308 [PMID: 16363014 DOI: 10.1002/bjs.5216]

37 **King PM**, Blazeby JM, Ewings P, Kennedy RH. Detailed evaluation of functional recovery following laparoscopic or open surgery for colorectal cancer within an enhanced recovery programme. *Int J Colorectal Dis* 2008; **23**: 795-800 [PMID: 18465136 DOI: 10.1007/s00384-008-0478-0]

38 **Lacy AM**, García-Valdecasas JC, Delgado S, Castells A, Taurá P, Piqué JM, Visa J. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. *Lancet* 2002; **359**: 2224-2229 [PMID: 12103285 DOI: 10.1016/S0140-6736(02)09290-5]

39 **Lacy AM**, Delgado S, Castells A, Prins HA, Arroyo V, Ibarzabal A, Pique JM. The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. *Ann Surg* 2008; **248**: 1-7 [PMID: 18580199 DOI: 10.1097/SLA.0b013e31816a9d65]

40 **Guillou PJ**, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, Heath RM, Brown JM; MRC CLASICC trial group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *Lancet* 1; **365**: 1718-1726 [PMID: 15894098 DOI: 10.1016/S0140-6736(05)66545-2]

41 **Veldkamp R**, Kuhry E, Hop WC, Jeekel J, Kazemier G, Bonjer HJ, Haglind E, Påhlman L, Cuesta MA, Msika S, Morino M, Lacy AM; COlon cancer Laparoscopic or Open Resection Study Group (COLOR). Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. *Lancet Oncol* 2005; **6**: 477-484 [PMID: 15992696 DOI: 10.1016/S1470-2045(05)70221-7]

42 **Hewett PJ**, Allardyce RA, Bagshaw PF, Frampton CM, Frizelle FA, Rieger NA, Smith JS, Solomon MJ, Stephens JH, Stevenson AR. Short-term outcomes of the Australasian randomized clinical study comparing laparoscopic and conventional open surgical treatments for colon cancer: the ALCCaS trial. *Ann Surg* 2008; **248**: 728-738 [PMID: 18948799 DOI: 10.1097/SLA.0b013e31818b7595]

43 **Kang JC**, Chung MH, Chao PC, Yeh CC, Hsiao CW, Lee TY, Jao SW. Hand-assisted laparoscopic colectomy vs open colectomy: a prospective randomized study.*Surg Endosc* 2004; **18**: 577-581 [PMID: 15026923 DOI: 10.1007/s00464-003-8148-3]

44 **Chung CC**, Ng DC, Tsang WW, Tang WL, Yau KK, Cheung HY, Wong JC, Li MK. Hand-assisted laparoscopic versus open right colectomy: a randomized controlled trial. *Ann Surg* 2007; **246**: 728-733 [PMID: 17968162 DOI: 10.1097/SLA.0b013e318123fbdf]

45 **Kim IY**, Kim BR, Kim YW. The short-term and oncologic outcomes of laparoscopic versus open surgery for T4 colon cancer. *Surg Endosc* 2016; **30**: 1508-1518 [PMID: 26123346 DOI: 10.1007/s00464-015-4364-x]

46 **Colon Cancer Laparoscopic or Open Resection Study Group.**, Buunen M, Veldkamp R, Hop WC, Kuhry E, Jeekel J, Haglind E, Påhlman L, Cuesta MA, Msika S, Morino M, Lacy A, Bonjer HJ. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. *Lancet Oncol* 2009; **10**: 44-52 [PMID: 19071061 DOI: 10.1016/S1470-2045(08)70310-3]

47 **Jayne DG**, Guillou PJ, Thorpe H, Quirke P, Copeland J, Smith AM, Heath RM, Brown JM; UK MRC CLASICC Trial Group. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. *J Clin Oncol* 2007; **25**: 3061-3068 [PMID: 17634484 DOI: 10.1200/JCO.2006.09.7758]

48 **Green BL**, Marshall HC, Collinson F, Quirke P, Guillou P, Jayne DG, Brown JM. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. *Br J Surg* 2013; **100**: 75-82 [PMID: 23132548 DOI: 10.1002/bjs.8945]

49 **Clinical Outcomes of Surgical Therapy Study Group.**, Nelson H, Sargent DJ, Wieand HS, Fleshman J, Anvari M, Stryker SJ, Beart RW Jr, Hellinger M, Flanagan R Jr, Peters W, Ota D. A comparison of laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med* 2004; **350**: 2050-2059 [PMID: 15141043 DOI: 10.1056/NEJMoa032651]

50 **Fleshman J**, Sargent DJ, Green E, Anvari M, Stryker SJ, Beart RW Jr, Hellinger M, Flanagan R Jr, Peters W, Nelson H; Clinical Outcomes of Surgical Therapy Study Group. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. *Ann Surg* 2007; **246**: 655-62; discussion 662-4 [PMID: 17893502 DOI: 0.1097/SLA.0b013e318155a762]

51 **Mathis KL**, Nelson H. Controversies in laparoscopy for colon and rectal cancer. *Surg Oncol Clin N Am* 2014; **23**: 35-47 [PMID: 24267164 DOI: 10.1016/j.soc.2013.09.006]

52 **McKay GD**, Morgan MJ, Wong SK, Gatenby AH, Fulham SB, Ahmed KW, Toh JW, Hanna M, Hitos K. Improved short-term outcomes of laparoscopic versus open resection for colon and rectal cancer in an area health service: a multicenter study. *Dis Colon Rectum* 2012; **55**: 42-50 [PMID: 22156866 DOI: 10.1097/DCR.0b013e318239341f]

53 **Dobbins TA**, Young JM, Solomon MJ. Uptake and outcomes of laparoscopically assisted resection for colon and rectal cancer in Australia: a population-based study. *Dis Colon Rectum* 2014; **57**: 415-422 [PMID: 24608296 DOI: 10.1097/DCR.0000000000000060]

**P-Reviewer:** Horesh N, Gurkan A **S-Editor:** Cui LJ **L-Editor: E-Editor:**

**Specialty type:** Surgery

**Country of origin:** Romania

**Peer-review report classification**

Grade A (Excellent): A, A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Characteristics of the included studies**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country of origin** | **Study type** | **Study period** | **Female**  **(number, L/O)** | **Mean age (yr, L/O)** | **Intervention (L-CME)**  **right/transverse/left location of the tumor** | **Control (O-CME) right/transverse/left location of the tumor** | **Adjuvant chemotherapy** |
| Kim *et al*[23], 2016 | Korea | Case control, unicentre, prospective database | 2008-2013 | 6244 | 69/67 | 116/0/0 | 99/0/0 | L-CME = 68 pts (58.62%), O-CME = 78 pts (78.78%), recommended to all stage II and III |
| Storli *et al*[22], 2016 | Norway | Prospective non RT, unicentre | 2007-2014 | 22/13 | 73/23 | 0/33/0 | 0/23/0 | L-CME = 8 (61.5%), O-CME = 5 (62.5%), all stage III below 75 yr |
| Huang *et al*[24], 2015 | China | Case control, unicentre | 2012 - 2013 | 20/21 | 56/55 | 53/0/0 | 49/0/0 | NR |
| Yamamoto *et al*[20], 2014 | Japan | RCT, multicentre | 2004-2009 | 248/215 | 64/64 | 144/0/389 | 156/0/368 | NR, recommended for all stage III |
| Munkedal *et al*[25], 2014 | Denmark | Prospective nonRT, unicentre | 2008-2011 | 30/38 | 69.1/72.9 | 30/0/53 | 41/0/38 | NR |
| Bae *et al*[27], 2014 | Korea | Case control, unicentre | 2006-2008 | 40/38 | 64/65 | 73/12/0 | 76/9/0 | All stage III and II with poor prognosis |
| Han *et al*[26], 2014 | China | Case control, unicentre | 2003-2010 | 94/67 | 67/65 | 177/0/0 | 147/0/0 | NR, recommended for high risk stage II and stage III |
| Zhao *et al*[28], 2014 | China | Case control, multicentre | 2000-2009 | 53/44 | 61.3/64.5 | 89/30/0 | 65/36/0 | NR, recommended for high risk stage II and stage III |
| Cong *et al*[29], 2014 | China | Case control, unicentre | 2008-2011 | 53/45 | 61.5/62.3 | 96/0/0 | 82/0/0 | NR |
| Storli *et al*[30], 2013 | Norway | Prospective nonRT, unicentre | 2007-2010 | 49/60 | 71.9/73.1 | 50/18/60  2 pts - multiple | 35/44/42 | All stage III below 75 yr |
| Gouvas *et al*[31], 2012 | Greece | Prospective nonRT, multicentric | 2006-2010 | 19/17 | 62.1/66.3 | 7/9/33 | 9/9/23 | NR |
| Sun *et al*[32], 2012 | China | Case control, unicentre | 2000-2008 | 58/45 | 60.1/61.9 | 49/7/91 | 43/9/74 | NR, according to stage |

L-CME: Laparoscopic complete mesocolic excision; O-CME: Open complete mesocolic excision; RT: Randomized control trial; Non RT: Non randomized control trial; L/O: Laparoscopy/open groups; NR: Not reported.

**Table 2 Quality assessment of included non-randomized controlled trials**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Quality evaluation criteria** | **Kim *et al*[23], 2016** | **Storli *et al*[22], 2016** | **Storli *et al*[30], 2016** | **Huang *et al*[24], 2015** | **Munkedal *et al*[25], 2014** | **Bae *et al*[27], 2014** | **Han *et al*[26], 2014** | **Zhao *et al*[28], 2014** | **Cong *et al*[29], 2014** | **Gouvas *et al*[31], 2012** | **Sun *et al*[32], 2012** |
| Clear stated aim | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Inclusion of consecutive patients | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 |
| Prospective data collection | 2 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 0 |
| Endpoints appropriate to  the study aim | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Unbiased assessment of  study end-point | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 |
| Appropriate follow-up period | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Loss to follow-up less than 5% | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 1 |
| Prospective calculation of the study size | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adequate group control | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 |
| Contemporary groups | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Baseline equivalence | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Adequate statistical analysis | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Total | 21 | 22 | 22 | 18 | 22 | 20 | 20 | 18 | 15 | 22 | 17 |

0: Non-reported; 1: Reported but inadequate; 2: Reported and adequate.


**Table 3 Results of meta-analysis comparing laparoscopic with open complete mesocolic excision for colon cancer**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Outcome or subgroups** | **Number of Studies** | **Participants** | **Statistical method,**  **(95%CI)** | **Effect estimate (95%CI)** | ***P* value** | | **Heterogeneity *P*, *I2***  **(%)** |
| Survival and recurrences | | | | | | | |
| Overall survival | 6 | 1777 | OR (M-H, random) | 1.32 (0.83, 2.10) | 0.24 | 0.002, 70 | |
| Three-year | 4 | 1010 | OR (M-H, random) | 2.02 (1.31, 3.12) | 0.001 | 0.24, 28 | |
| Five-year | 3 | 767 | OR (M-H, random) | 0.77 (0.44, 1.37) | 0.38 | 0.07, 63 | |
| Disease free survival | 4 | 856 | OR (M-H, random) | 1.15 (0.70, 1.87) | 0.58 | 0.09, 54 | |
| Three-year | 3 | 686 | OR (M-H, random) | 1.45 (1.00, 2.10) | 0.05 | 0.89, 0 | |
| Five-year | 1 | 170 | OR (M-H, random) | 0.50 (0.24, 1.05) | 0.07 | NA | |
| Local recurrences | 5 | 1233 | OR (M-H, fixed) | 0.67 (0.38, 1.17) | 0.16 | 0.60, 0 | |
| One-year | 2 | 466 | OR (M-H, fixed) | 0.52 (0.20, 1.35) | 0.18 | 0.30, 7 | |
| Five-year | 3 | 767 | OR (M-H, fixed) | 0.77 (0.38, 1.54) | 0.46 | 0.52, 0 | |
| Distant recurrences | 4 | 1018 | OR (M-H, random) | 0.98 (0.61, 1.58) | 0.94 | 0.17, 40 | |
| Three-year | 1 | 251 | OR (M-H, random) | 1.28 (0.54, 3.03) | 0.58 | NA | |
| Five-year | 3 | 767 | OR (M-H, random) | 0.90 (0.48, 1.69) | 0.75 | 0.10, 57 | |
| Port site metastasis | 2 | 494 | OR (M-H, fixed) | 1.52 (0.20, 11.42) | 0.69 | 0.55, 0 | |
| Quality of the resected specimen | | | | | | | |
| Lymphnodes retrieved | 10 | 2647 | MD (IV, random) | -1.06 (-3.65, 1.53) | 0.42 | < 0.001, 92 | |
| RCTs | 1 | 1057 | MD (IV, random) | 1.00 (-0.34, 2.34) | 0.14 | NA | |
| NRCTs | 9 | 1590 | MD (IV, random) | -1.32 (-4.42, 1.78) | 0.40 | < 0.001, 92 | |
| Lymphnodes retrieved | 10 | 2647 | MD (IV, random) | -1.06 (-3.65, 1.53) | 0.42 | < 0.001, 92 | |
| < 100 patients | 4 | 478 | MD (IV, random) | -3.18 (-8.69, 2.33) | 0.26 | < 0.001, 85 | |
| > 100 patients | 6 | 2169 | MD (IV, random) | 0.29 (-1.64, 2.21) | 0.77 | < 0.001, 83 | |
| Lymphnodes retrieved | 10 | 2647 | MD (IV, random) | -1.06 (-3.65, 1.53) | 0.42 | < 0.001, 92 | |
| Europe | 4 | 559 | MD (IV, random) | -3.33 (-8.31, 1.64) | 0.19 | < 0.001, 90 | |
| Asia | 6 | 2088 | MD (IV, random) | 0.56 (-1.33, 2.46) | 0.56 | < 0.001, 77 | |
| Tumor to arterial high tie (mm) | 2 | 252 | MD (IV, random) | 14.26 (-4.30, 32.82) | 0.13 | < 0.001, 92 | |
| Resected mesocolon surface (cm2) | 2 | 252 | MD (IV, fixed) | 11.75 (9.50, 13.99) | < 0.001 | 0.55, 0 | |
| Complete mesocolic plane excision | 1 | 90 | OR (M-H, fixed) | 0.77 (0.20, 2.96) | 0.71 | NA | |
| Operative data | | | | | | | |
| Duration of surgery | 7 | 2266 | MD (IV, random) | 26.26 (5.06, 47.46) | 0.02 | < 0.001, 94 | |
| Incision length (cm) | 2 | 1159 | MD (IV, random) | -14.01 (-14.35, -13.66) | < 0.001 | 0.89, 0 | |
| Blood loss (mL) | 5 | 1868 | MD (IV, random) | -52.11 (-78.57, -25.65) | < 0.001 | < 0.001, 89 | |
| Transfusion requirement | 2 | 1272 | OR (M-H, random) | 0.45 (0.27, 0.75) | 0.002 | 0.54, 0 | |
| Intraoperative morbidity | 1 | 1057 | OR (M-H, fixed) | 2.12 (0.95, 4.72) | 0.07 | NA | |
| Postoperative course | | | | | | | |
| Time to first flatus (d) | 4 | 1771 | MD (IV, random) | -0.90 (-1.46, -0.34) | 0.002 | < 0.001, 97 | |
| Time to liquid diet (d) | 5 | 1031 | MD (IV, random) | -1.84 (-2.93, -0.74) | 0.001 | < 0.001, 98 | |
| Short-term morbidity and mortality | | | | | | | |
| Thirty-day overall morbidity | 7 | 2144 | OR (M-H, fixed) | 0.57 (0.46, 0.71) | < 0.001 | 0.76, 0 | |
| RCTs | 1 | 1057 | OR (M-H, fixed) | 0.66 (0.49, 0.89) | 0.006 | NA | |
| NRCTs | 6 | 1087 | OR (M-H, fixed) | 0.49 (0.36, 0.68) | < 0.001 | 0.89, 0 | |
| Wound complications | 8 | 2322 | OR (M-H, fixed) | 0.43 (0.30, 0.61) | < 0.001 | 0.80, 0 | |
| Postoperative bleeding | 4 | 1662 | OR (M-H, fixed) | 1.20 (0.46, 3.12) | 0.71 | 0.75, 0 | |
| Pneumonia | 5 | 867 | OR (M-H, random) | 0.61 (0.20, 1.84) | 0.38 | 0.21, 32 | |
| Anastomotic leakage | 8 | 2471 | OR (M-H, fixed) | 0.82 (0.54, 1.25) | 0.36 | 0.77, 0 | |
| Need for reoperation | 2 | 1113 | OR (M-H, fixed) | 0.59 (0.28, 1.23) | 0.16 | 0.79, 0 | |
| Thirty-day mortality | 6 | 2237 | OR (M-H, fixed) | 0.42 (0.16, 1.12) | 0.07 | 0.98, 0 | |
| Hospital stay (d) | 9 | 2573 | MD (IV, random) | -4.07 (-5.87, -2.28) | < 0.001 | < 0.001, 91 | |


M-H: Mantel-haenszel analysis method; IV: Inverse variance analysis method; RCT: Randomized control trial; NRCs: Non-randomized control trials; MD: Mean difference; OR: Odds ratio; NA: Not applicable.




**Figure 1 Flow diagram of the systematic literature search and study selection according to prisma statement.** RCT: Randomized control trial; CCT: Controlled clinical trial.




**Figure 2 Meta-analysis of studies on overall survival of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.**




**Figure 3 Results of statistical analysis.** A: Meta-regression on three-year overall survival according with the number of included patients in each study, of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer; B: Subgroup meta-analysis according with the selection of patients with only right colon cancers (Yes group) or all-localizations colon cancer (No group); C: Cumulative meta-analysis according to the year of publishing for each study.




**Figure 4 Meta-analysis of studies on disease-free survival of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.**




**Figure 5 Meta-regression of studies on three-year disease-free survival of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.**




**Figure 6 Meta-analysis of studies local recurrence rate of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.**




**Figure 7 Meta-analysis of studies on lymphnodes retrieved of the specimen of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.**




**Figure 8 Results of statistical analysis.** A: Meta-regression of studies on lymphnodes retrieved of the specimen according to the number of the included patients in each study; B: Cumulative meta-analysis according to the year of publishing of the article of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.




**Figure 9 Meta-analysis of studies on tumor to arterial high tie (mm) distance of the specimen of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.**




**Figure 10 Meta-analysis of studies on resected mesocolon surface (cm2) of the specimen of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.**




**Figure 11 Meta-analysis of studies on transfusion requirements of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.**




**Figure 12 Meta-analysis of studies on postoperative overall morbidity of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.**

****

**Figure 13 Leave-one-out Meta-Analysis for the endpoint number of retrieved lymphnodes of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.**



**Figure 14 Begg’s funnel plot for the endpoint number of retrieved lymphnodes of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.** RCTs: Randomized control trial; NRCTs: Non-randomized clinical studies.



**Figure 15 Begg’s funnel plot for the endpoint overall survival of patients undergoing laparoscopic *vs* open complete mesocolic excision with central vascular ligation excision for colon cancer.**